Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

Clinical Cancer Research 13, 2488-2495, April 15, 2007. doi: 10.1158/1078-0432.CCR-06-1592
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, H.
Right arrow Articles by Mani, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, H.
Right arrow Articles by Mani, S.

Cancer Therapy: Preclinical

Activated Pregnenolone X-Receptor Is a Target for Ketoconazole and Its Analogs

Hongwei Wang1,2, Haiyan Huang1,2, Hao Li1,2, Denise G. Teotico8, Michael Sinz5, Sharyn D. Baker6, Jeffrey Staudinger7, Ganjam Kalpana1,4, Matthew R. Redinbo8 and Sridhar Mani1,2,4

Authors' Affiliations: 1 Albert Einstein Cancer Center, Departments of 2 Medicine, 3 Pathology, and 4 Molecular Genetics, Albert Einstein College of Medicine, Bronx, New York; 5 Bristol Myers Squibb Co. Wallingford, Connecticut; 6 Johns Hopkins University, Baltimore, Maryland; 7 University of Kansas, Lawrence, Kansas; and 8 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Requests for reprints: Sridhar Mani, Albert Einstein Cancer Center, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Chanin 302D-1, Bronx, NY 10461. Phone: 718-430-2871; Fax: 718-904-2892; E-mail: smani{at}montefiore.org.

Purpose: Variations in biotransformation and elimination of microtubule-binding drugs are a major cause of unpredictable side effects during cancer therapy. Because the orphan receptor, pregnenolone X-receptor (PXR), coordinately regulates the expression of paclitaxel metabolizing and transport enzymes, controlling this process could improve therapeutic outcome.

Experimental Design: In vitro RNA-, protein-, and transcription-based assays in multiple cell lines derived from hepatocytes and PXR wild-type and null mouse studies were employed to show the effects of ketoconazole and its analogues on ligand-activated PXR-mediated gene transcription and translation.

Results: The transcriptional activation of genes regulating biotransformation and transport by the liganded human nuclear xenobiotic receptor, PXR, was inhibited by the commonly used antifungal ketoconazole and related azole analogs. Mutations at the AF-2 surface of the human PXR ligand-binding domain indicate that ketoconazole may interact with specific residues outside the ligand-binding pocket. Furthermore, in contrast to that observed in PXR (+/+) mice, genetic loss of PXR results in increased (preserved) blood levels of paclitaxel.

Conclusions: These studies show that some azole compounds repress the coordinated activation of genes involved in drug metabolism by blocking PXR activation. Because loss of PXR maintains blood levels of paclitaxel upon chronic dosing, ketoconazole analogues may also serve to preserve paclitaxel blood levels on chronic dosing of drugs. Our observations may facilitate new strategies to improve the clinical efficacy of drugs and to reduce therapeutic side effects.




This article has been cited by other articles:


Home page
Toxicol SciHome page
R. J. Kavlock, G. Ankley, J. Blancato, M. Breen, R. Conolly, D. Dix, K. Houck, E. Hubal, R. Judson, J. Rabinowitz, et al.
Computational Toxicology--A State of the Science Mini Review
Toxicol. Sci., May 1, 2008; 103(1): 14 - 27.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
H. Wang, H. Li, L. B. Moore, M. D. L. Johnson, J. M. Maglich, B. Goodwin, O. R. R. Ittoop, B. Wisely, K. Creech, D. J. Parks, et al.
The Phytoestrogen Coumestrol Is a Naturally Occurring Antagonist of the Human Pregnane X Receptor
Mol. Endocrinol., April 1, 2008; 22(4): 838 - 857.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
L. Svecova, R. Vrzal, L. Burysek, E. Anzenbacherova, L. Cerveny, J. Grim, F. Trejtnar, J. Kunes, M. Pour, F. Staud, et al.
Azole Antimycotics Differentially Affect Rifampicin-Induced Pregnane X Receptor-Mediated CYP3A4 Gene Expression
Drug Metab. Dispos., February 1, 2008; 36(2): 339 - 348.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Ekins, C. Chang, S. Mani, M. D. Krasowski, E. J. Reschly, M. Iyer, V. Kholodovych, N. Ai, W. J. Welsh, M. Sinz, et al.
Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites
Mol. Pharmacol., September 1, 2007; 72(3): 592 - 603.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2007 by the American Association for Cancer Research.